Boxlight Corporation, a provider of interactive technology solutions, has announced its financial results for the third quarter of 2026, revealing significant improvements in revenue and profitability metrics.
The company reported a revenue of $30.1 million for the quarter, marking a 2.5% increase compared to the same period last year. Additionally, Boxlight's gross profit margin improved significantly, rising to 37.1%, up from 29.1% in the prior year quarter. This reflects an increase of 800 basis points, showcasing the company's efforts to enhance operational efficiency.
Boxlight's net loss also narrowed considerably, coming in at $1.0 million, which is an 83.5% improvement from a net loss of $6.2 million reported in the same quarter of the previous year. The adjusted EBITDA for the quarter was reported at $2.4 million, further indicating the company's positive trajectory.
Founded in Nevada, Boxlight operates within the educational services sector, focusing on providing innovative solutions for interactive learning environments. The company trades on the Nasdaq under the ticker symbol BOXL.
This filing, dated November 17, 2026, includes detailed financial statements and exhibits. The press release announcing these results is attached as Exhibit 99.1 and is incorporated by reference in the filing.
As Boxlight continues to refine its business model and expand its offerings, industry competitors will be closely monitoring these developments. The educational services sector, represented by the SIC code 8200, is characterized by a competitive landscape where advancements in technology are crucial for maintaining market share.
Looking ahead, further updates on Boxlight's performance and strategic initiatives are anticipated. The filing does not specify what happens next, but the company's recent focus on improving financial health suggests a commitment to ongoing growth and innovation.
Read Next
Amer Sports Reports Q3 2026 Financial Results
Millicom launches offering of Senior Notes due 2033
MetaVia completes Phase 1 trial for DA-1726 dual-receptor agonist
Nuo Therapeutics Reports Strong Q3 2026 Financial Results
MarineMax amends SEC filing to correct financial statement date
Worthington Enterprises presents at Baird 2026 Global Industrial Conference








